Key Points
- COO Julie Rubinstein sold 19,060 shares on April 20 at an average price of $14.55 (≈$277,323), the transaction was executed under a pre-arranged Rule 10b5-1 plan and reduced her stake to 399,484 shares (a 4.55% decrease, ≈$5.81M).
- Across mid-March to April she disposed of roughly 233,422 shares in multiple transactions (including two 30,941-share blocks), reflecting a sustained selling program over several weeks.
- Adaptive Biotechnologies has a $2.19 billion market cap, recently beat quarterly revenue and EPS estimates with revenue up 51% year-over-year, and carries a consensus analyst rating of "Moderate Buy" with a $18.25 price target.
Adaptive Biotechnologies Corporation (NASDAQ:ADPT - Get Free Report) COO Julie Rubinstein sold 19,060 shares of the stock in a transaction on Monday, April 20th. The shares were sold at an average price of $14.55, for a total value of $277,323.00. Following the sale, the chief operating officer owned 399,484 shares in the company, valued at approximately $5,812,492.20. This represents a 4.55% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Julie Rubinstein also recently made the following trade(s):
- On Tuesday, April 21st, Julie Rubinstein sold 30,941 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $14.66, for a total value of $453,595.06.
- On Thursday, April 16th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $14.18, for a total value of $270,270.80.
- On Monday, April 13th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $13.15, for a total value of $250,639.00.
- On Friday, April 10th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $12.77, for a total value of $243,396.20.
- On Tuesday, April 7th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $13.56, for a total value of $258,453.60.
- On Wednesday, April 8th, Julie Rubinstein sold 30,941 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $14.83, for a total value of $458,855.03.
- On Wednesday, April 1st, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $14.45, for a total value of $275,417.00.
- On Monday, March 23rd, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $13.83, for a total value of $263,599.80.
- On Friday, March 20th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $13.37, for a total value of $254,832.20.
- On Wednesday, March 18th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $13.18, for a total value of $251,210.80.
Adaptive Biotechnologies Price Performance
ADPT stock opened at $14.21 on Wednesday. The company has a market cap of $2.19 billion, a P/E ratio of -35.52 and a beta of 2.29. Adaptive Biotechnologies Corporation has a 1 year low of $6.90 and a 1 year high of $20.76. The stock's fifty day moving average price is $14.61 and its 200-day moving average price is $16.00.
Adaptive Biotechnologies (NASDAQ:ADPT - Get Free Report) last released its quarterly earnings results on Thursday, February 5th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.19) by $0.10. The firm had revenue of $71.68 million for the quarter, compared to the consensus estimate of $59.38 million. Adaptive Biotechnologies had a negative return on equity of 46.68% and a negative net margin of 21.48%.The company's revenue for the quarter was up 51.0% on a year-over-year basis. During the same period last year, the business posted ($0.23) EPS. As a group, analysts expect that Adaptive Biotechnologies Corporation will post -0.5 earnings per share for the current year.
Analysts Set New Price Targets
ADPT has been the topic of a number of research reports. Piper Sandler set a $21.00 price target on Adaptive Biotechnologies in a research note on Friday, February 6th. Wall Street Zen cut Adaptive Biotechnologies from a "buy" rating to a "hold" rating in a report on Saturday, March 7th. BTIG Research raised their target price on Adaptive Biotechnologies from $21.00 to $22.00 and gave the stock a "buy" rating in a report on Friday, February 6th. Guggenheim raised their target price on Adaptive Biotechnologies from $20.00 to $21.00 and gave the stock a "buy" rating in a report on Monday, January 26th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Adaptive Biotechnologies in a report on Wednesday, January 21st. Seven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Adaptive Biotechnologies has an average rating of "Moderate Buy" and a consensus price target of $18.25.
View Our Latest Report on Adaptive Biotechnologies
Institutional Investors Weigh In On Adaptive Biotechnologies
A number of institutional investors and hedge funds have recently bought and sold shares of the business. Contravisory Investment Management Inc. bought a new stake in Adaptive Biotechnologies during the first quarter valued at about $202,000. SG Americas Securities LLC raised its holdings in Adaptive Biotechnologies by 37.8% during the first quarter. SG Americas Securities LLC now owns 137,758 shares of the company's stock valued at $1,912,000 after acquiring an additional 37,823 shares during the period. Diversified Trust Co raised its holdings in Adaptive Biotechnologies by 8.5% during the first quarter. Diversified Trust Co now owns 45,776 shares of the company's stock valued at $635,000 after acquiring an additional 3,576 shares during the period. Rockefeller Capital Management L.P. raised its holdings in Adaptive Biotechnologies by 50.7% during the fourth quarter. Rockefeller Capital Management L.P. now owns 7,577 shares of the company's stock valued at $123,000 after acquiring an additional 2,550 shares during the period. Finally, Corient Private Wealth LLC raised its holdings in Adaptive Biotechnologies by 3.4% during the fourth quarter. Corient Private Wealth LLC now owns 71,908 shares of the company's stock valued at $1,168,000 after acquiring an additional 2,347 shares during the period. 99.17% of the stock is owned by institutional investors.
About Adaptive Biotechnologies
(
Get Free Report)
Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.
The company's flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
